Discovery of Tetrahydropyrazolopyrazine Derivatives as Potent and Selective MYT1 Inhibitors for the Treatment of...

Area of Science:

• Oncology
• Drug Discovery
• Biochemistry

Background:

• Breast and gynecological cancers are leading causes of mortality in women globally.
• There is a critical need for novel therapeutic strategies to combat these diseases.
• MYT1 kinase presents a potential new target for cancer therapy.

Purpose of the Study:

• To identify and validate MYT1 as a therapeutic target for breast and gynecological cancers.
• To develop novel, potent, and selective MYT1 inhibitors using structure-based drug design.
• To evaluate the preclinical efficacy and safety profile of a lead MYT1 inhibitor.

Main Methods:

• Utilized PandaOmics, an AI platform, for target discovery.
• Employed structure-based drug design to develop MYT1 inhibitors.
• Assessed compound selectivity against related kinases like WEE1.
• Conducted pharmacokinetic and in vivo antitumor efficacy studies.

Main Results:

• MYT1 was identified as a promising therapeutic target, particularly in tumors with CCNE1 amplification.
• Novel MYT1 inhibitors were synthesized, with a lead compound featuring a tetrahydropyrazolopyrazine ring.
• The lead compound demonstrated high selectivity for MYT1 over WEE1, minimizing potential side effects.
• Compound 21 exhibited favorable pharmacokinetic properties and significant in vivo antitumor activity.

Conclusions:

• MYT1 is a viable therapeutic target for breast and gynecological cancers.
• Compound 21 represents a promising novel MYT1 inhibitor with potential for clinical development.
• The developed inhibitors offer a selective approach to targeting MYT1, potentially improving treatment outcomes.